HALOZYME THERAPEUTICS, INC.HALOEarnings & Financial Report
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
Revenue
$298.0M
Gross Profit
$256.0M
Operating Profit
$175.5M
Net Profit
$137.0M
Gross Margin
85.9%
Operating Margin
58.9%
Net Margin
46.0%
YoY Growth
29.5%
EPS
$1.06
Financial Flow
HALOZYME THERAPEUTICS, INC. Q4 2024 Financial Summary
HALOZYME THERAPEUTICS, INC. reported revenue of $298.0M (up 29.5% YoY) for Q4 2024, with a net profit of $137.0M (up 60.5% YoY) (46.0% margin). Cost of goods sold was $42.1M, operating expenses totaled $80.5M.
Key Financial Metrics
| Total Revenue | $298.0M |
|---|---|
| Net Profit | $137.0M |
| Gross Margin | 85.9% |
| Operating Margin | 58.9% |
| Report Period | Q4 2024 |
Revenue Breakdown
HALOZYME THERAPEUTICS, INC. Q4 2024 revenue of $298.0M breaks down across 6 segments, led by Royalty at $170.4M (57.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Royalty | $170.4M | 57.2% |
| Collaborative Agreements | $48.2M | 16.2% |
| Proprietary Products Sales | $47.3M | 15.9% |
| Event Based Development And Regulatory Milestone And Other Fees | $15.0M | 5.0% |
| Device Partnered Products | $12.4M | 4.1% |
| Device Licensing And Development | $3.2M | 1.1% |
HALOZYME THERAPEUTICS, INC. Revenue by Segment — Quarterly Trend
HALOZYME THERAPEUTICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Royalty and Collaborative Agreements) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Royalty | $258.0M | $236.0M | $205.6M | $168.2M |
| Collaborative Agreements | — | — | — | $18.6M |
| Proprietary Products Sales | $59.6M | $52.2M | $46.5M | $36.3M |
| Event Based Development And Regulatory Milestone And Other Fees | — | — | $24.5M | — |
| Device Partnered Products | $12.9M | $9.5M | $11.8M | $14.7M |
HALOZYME THERAPEUTICS, INC. Annual Revenue by Year
HALOZYME THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.4B |
| 2024 | $1.0B |
| 2023 | $829.3M |
| 2022 | $660.1M |
HALOZYME THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
HALOZYME THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $451.8M | +51.6% | $-141.6M | -31.3% |
| Q3 2025 | $354.3M | +22.1% | $175.2M | 49.5% |
| Q2 2025 | $325.7M | +40.8% | $165.2M | 50.7% |
| Q1 2025 | $264.9M | +35.2% | $118.1M | 44.6% |
| Q4 2024 | $298.0M | +29.5% | $137.0M | 46.0% |
| Q3 2024 | $290.1M | +34.3% | $137.0M | 47.2% |
| Q2 2024 | $231.4M | +4.7% | $93.2M | 40.3% |
| Q1 2024 | $195.9M | +20.8% | $76.8M | 39.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $195.9M | $231.4M | $290.1M | $298.0M | $264.9M | $325.7M | $354.3M | $451.8M |
| YoY Growth | 20.8% | 4.7% | 34.3% | 29.5% | 35.2% | 40.8% | 22.1% | 51.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.84B | $1.97B | $2.12B | $2.06B | $2.20B | $2.05B | $2.22B | $2.53B |
| Liabilities | $1.66B | $1.68B | $1.67B | $1.70B | $1.71B | $1.72B | $1.72B | $2.48B |
| Equity | $177.8M | $289.4M | $452.7M | $363.8M | $482.3M | $332.7M | $503.9M | $48.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $129.4M | $55.8M | $115.4M | $178.5M | $154.2M | $99.7M | $178.6M | $219.0M |